Dramatic response of a negative PD-L1 expression and TMB low pulmonary sarcomatoid carcinoma to sintilimab combined with anlotinib
Open Journal of Clinical and Medical Case Reports · 2023
DOI: 10.52768/2379-1039/1969 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Journal of Clinical and Medical Case Reports, 2023. Verfasst von Likun Liuone.
Abstract (Originalsprache)
Pulmonary Sarcomatoid Carcinoma (PSC) is a rare and highly malignant subtype of Non Small Cell Lung Cancer (NSCLC). In contrast to other types of lung cancers, recent retrospective studies demonstrated that PSC always shows frequent genetic mutations, high TMB and high PD L1 expression which indicates these patients might derive survival benefits from immune checkpoint inhibitors
Zitieren
APA
Liuone, L. (2023). Dramatic response of a negative PD-L1 expression and TMB low pulmonary sarcomatoid carcinoma to sintilimab combined with anlotinib. Open Journal of Clinical and Medical Case Reports. https://doi.org/10.52768/2379-1039/1969
Vancouver
Liuone L. Dramatic response of a negative PD-L1 expression and TMB low pulmonary sarcomatoid carcinoma to sintilimab combined with anlotinib. Open Journal of Clinical and Medical Case Reports. 2023. doi:10.52768/2379-1039/1969
BibTeX
@article{Liuone2023,
author = {Liuone, Likun},
title = {Dramatic response of a negative PD-L1 expression and TMB low pulmonary sarcomatoid carcinoma to sintilimab combined with anlotinib},
journal = {Open Journal of Clinical and Medical Case Reports},
year = {2023},
doi = {10.52768/2379-1039/1969}
}
EUVIMED